US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,809.53

+37.321.35%

Number of Gainers:4

Number of Losers:1

Number of Flat:- -

PE:- -

High:2,843.20

Open:2,773.64

Low:2,762.59

Close:2,772.21

Volume:8.62M

Turnover:176.88M

Market Cap:44.92B

Float Cap:41.95B

Loading ...

Veru Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall

Veru Q3 Net Loss Narrows on Lower G&A Expenses

Veru Q3 EPS $(0.30) Beats $(0.32) Estimate

Benzinga Earnings

Veru FY26 Q3 Net Loss Narrows to $7 Million; R&D Expense Rises 44% to $4.4 Million

Veru - Phase 2B Plateau Trial Fully Enrolled with 239 Patients

THOMSON REUTERS

Veru Q3 EPS USD -0.3

THOMSON REUTERS

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2B Plateau Clinical Trial Progress

THOMSON REUTERS

Press Release: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Plateau Clinical Trial Progress

Veru Inc. Expected to Post a Loss of 32 Cents a Share - Earnings Preview

Femasys Prices USD 30 Million Private Placement at USD 3.2 Per Share

Femasys Secures $30 Million Private Placement, with Potential Proceeds of up to $90 Million

THOMSON REUTERS

Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

MannKind Posts Transcript of Q2 2026 Earnings Call

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK4584/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2809.5261,"timestamp":1787342399999,"preClose":2772.205,"halted":0,"volume":8615466,"delay":0,"changeRate":0.013463,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":37.321045,"latestTime":"08-21 16:00:00 EDT","open":2773.6416,"high":2843.2031,"low":2762.586,"amount":176883492.694548,"amplitude":0.029081,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.743837,"peRate":70.810459,"turnoverRate":0.005996,"increases":4,"decrements":1,"flats":0,"marketCap":44921179196,"floatMarketCap":41949345425},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2843.2031,"amplitude":0.029081,"preClose":2772.205,"low":2762.586,"pbRate":"5.743837","latestPrice":2809.5261,"volume":8615466,"delay":0,"open":2773.6416,"prevYearClose":2379.9924,"prevWeekClose":2762.5803,"prevMonthClose":2636.2712,"prevQuarterClose":2562.5076,"fiveDayClose":2762.5803,"twentyDayClose":2335.9458,"sixtyDayClose":2579.5955,"secType":"PLATE","market":"US","turnoverRate":0.005996,"peRate":70.810459,"marketCap":44921179196,"floatMarketCap":41949345425,"timestamp":1787342399999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":4,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658931762","title":"Veru Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931762","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931762?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:31","pubTimestamp":1786368708,"startTime":"0","endTime":"0","summary":"Veru Inc. reports results for the quarter ended June 30 - Earnings SummaryVeru Inc.VERU.OQreported a quarterly adjusted loss of 30 cents per share for the quarter ended June 30, higher than the same q","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44715G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","VERU","BK4007","BK4183","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938420","title":"Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938420","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938420?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:11","pubTimestamp":1786360306,"startTime":"0","endTime":"0","summary":"Switzerland's MoonLake Q2 net loss narrows as expenses fallOverviewSwitzerland biopharma reported Q2 net loss as operating expenses declined from prior quarterCompany ended Q2 with $537 mln in cash an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N44709J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4539","BK4584","BK4007","BK4557","BK4183","VERU","BK4121","BK4139","RPID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980586","title":"Veru Q3 Net Loss Narrows on Lower G&A Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980586","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658980586?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:41","pubTimestamp":1786358505,"startTime":"0","endTime":"0","summary":"Veru Q3 net loss narrows on lower G&A expensesOverviewUS biopharmaceutical firm's fiscal Q3 net loss narrowed yr/yrCompany fully enrolled Phase 2b PLATEAU clinical trial for obesity, exceeding target ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N44708U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4567","BK4548","BK4183","ANIP","LGHT","BK4121","BK4504","BK4082","LU2177674079.SGD","RPID","VERU","RMD","BK4539","LU2008162690.USD","LU0566484027.USD","LU0170899867.USD","BK4557","LU1559883803.SGD","IE00B5TLWC47.USD","BK4588","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658987034","title":"Veru Q3 EPS $(0.30) Beats $(0.32) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658987034","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658987034?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:35","pubTimestamp":1786358104,"startTime":"0","endTime":"0","summary":"Veru (NASDAQ:VERU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 40 percent increase over losses of $(0.50) per share from the same period","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61068361/veru-q3-eps-0-30-beats-0-32-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU","BK4584","BK4007","BK4183","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658877869","title":"Veru FY26 Q3 Net Loss Narrows to $7 Million; R&D Expense Rises 44% to $4.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658877869","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658877869?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:30","pubTimestamp":1786357847,"startTime":"0","endTime":"0","summary":"Veru FY26 Q3 net loss narrows to $7 million; R&D expense rises 44% to $4.4 millionVeru posted a fiscal Q3 net loss of USD 7 million, or USD 0.30 per share, narrowing from USD 7.3 million, or USD 0.50.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL2kGMM4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4007","SG9999014039.USD","IE00BN0W2V16.EUR","BK4584","BK4588","BCDF","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014005.SGD","VERU","SG9999014021.USD","IE00B3QW5Z07.USD","BK4183","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658987751","title":"Veru - Phase 2B Plateau Trial Fully Enrolled with 239 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2658987751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658987751?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:30","pubTimestamp":1786357833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXFWRX9B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VERU","BK4584","BK4007","BK4557","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658987222","title":"Veru Q3 EPS USD -0.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2658987222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658987222?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:30","pubTimestamp":1786357833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXFWRX9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","BK4007","BK4557","BK4584","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658498722","title":"Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2B Plateau Clinical Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2658498722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658498722?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:30","pubTimestamp":1786357800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA5S5C66:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4007","BK4557","BK4183","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658987072","title":"Press Release: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Plateau Clinical Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2658987072","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658987072?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:30","pubTimestamp":1786357800,"startTime":"0","endTime":"0","summary":"-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients ---- Phase 2b PLATEAU clinical trial interim analysis and r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","USRD","NVIB","BK4022","BK4183","IDNA","HYLG","PRGS","VERU","BK4097","LU2065732104.USD","BK4232","JDOC","BK4557","BK4007","BK4584","R","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657647701","title":"Veru Inc. Expected to Post a Loss of 32 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657647701","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657647701?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:11","pubTimestamp":1786119080,"startTime":"0","endTime":"0","summary":"Veru Inc. <VERU.OQ> expected to post a loss of32cents a share - Earnings PreviewVeru Inc.VERU.OQVERU.Ois expected to  show no change in quarterly revenue when it reports  results on August 10 for the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N444222:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4584","BK4007","VERU","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657999649","title":"Femasys Prices USD 30 Million Private Placement at USD 3.2 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657999649","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657999649?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:25","pubTimestamp":1786109139,"startTime":"0","endTime":"0","summary":"Femasys prices USD 30 million private placement at USD 3.2 per shareFemasys priced a USD 30 million private placement of common stock, pre-funded warrants, and accompanying warrants with accredited in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL8ljZPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","BK4584","FEMY","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014039.USD","BK4585","BK4082","LU2210150020.SGD","BCDF","BK4112","IE00BGHQF748.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014021.USD","NDAQ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649951","title":"Femasys Secures $30 Million Private Placement, with Potential Proceeds of up to $90 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657649951?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:25","pubTimestamp":1786109115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA8WSKTW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","FEMY","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641561","title":"Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641561","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641561?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:25","pubTimestamp":1786109100,"startTime":"0","endTime":"0","summary":"-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug.  07, 2026  (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing trans","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341129/0/en/femasys-secures-30-million-private-placement-with-potential-proceeds-of-up-to-90-million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","BK4528","BK4539","BK4082","BK4205","FEMY","UK","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657284664","title":"MannKind Posts Transcript of Q2 2026 Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2657284664","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657284664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:12","pubTimestamp":1786061558,"startTime":"0","endTime":"0","summary":"MannKind posts transcript of Q2 2026 earnings callMannKind discussed Q2 2026 results on an Aug. 5 earnings call attended by CEO Michael Castagna, CFO Chris Prentiss.Revenue totaled 109.4 million, up 4","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL34qfm1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}]}}